US Penny Stocks To Watch In October 2024 #UKFinance
CashNews.co
As the U.S. stock market experiences mixed performances, with the S&P 500 and Nasdaq rising while the Dow continues its losing streak, investors are keenly observing economic indicators for signs of stability. In this context, penny stocks—though an older term—remain relevant as they often represent smaller or newer companies with potential growth opportunities at lower price points. When these stocks are supported by strong financial fundamentals, they can offer compelling prospects without some of the typical risks associated with this investment category.
Name
Share Price
Market Cap
Financial Health Rating
BAB (OTCPK:BABB)
$0.7553
$5.71M
★★★★★★
LexinFintech Holdings (NasdaqGS:LX)
$3.15
$526.12M
★★★★★★
RLX Technology (NYSE:RLX)
$1.60
$2.03B
★★★★★★
ARC Document Solutions (NYSE:ARC)
$3.43
$147.91M
★★★★★★
Permianville Royalty Trust (NYSE:PVL)
$1.58
$53.13M
★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)
$4.50
$69.71M
★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)
$3.68
$112.23M
★★★★★★
Better Choice (NYSEAM:BTTR)
$1.70
$2.96M
★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)
$1.30
$65.6M
★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)
$1.05
$96.23M
★★★★★☆
Click here to see the full list of 760 stocks from our US Penny Stocks screener.
We’ll examine a selection from our screener results.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Quince Therapeutics, Inc. is a biopharmaceutical company dedicated to acquiring, developing, and commercializing therapies for debilitating and rare diseases, with a market cap of $37.65 million.
Operations: Quince Therapeutics, Inc. has not reported any revenue segments.
Market Cap: $37.65M
Quince Therapeutics is a pre-revenue biopharmaceutical company with a market cap of US$37.65 million, focused on developing therapies for rare diseases. Despite an increased debt-to-equity ratio of 29.5% over five years, it maintains more cash than total debt and has not significantly diluted shareholders recently. The management team is relatively new, with an average tenure of 1.4 years, while the board is experienced at 5.6 years average tenure. Quince’s recent Phase 3 ATTeST trial results published in The Lancet Neurology showed promising safety data for its lead asset EryDex, which has received FDA Fast Track designation for treating Ataxia-Telangiectasia (A-T).
NasdaqGS:QNCX Debt to Equity History and Analysis as at Oct 2024
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Douglas Elliman Inc. operates in the real estate services and property technology investment sectors in the United States, with a market cap of approximately $146.01 million.
Operations: The company generates revenue primarily from its Real Estate Brokerage segment, which accounts for $951.67 million.
Market Cap: $146.01M
Douglas Elliman Inc. operates with a market cap of US$146.01 million, primarily generating revenue from its Real Estate Brokerage segment, which reported US$951.67 million in revenue recently. The company is currently unprofitable, with increased losses over the past five years and a negative return on equity at -32.21%. Despite having no debt and short-term assets covering short-term liabilities, long-term liabilities remain uncovered by current assets. Recent executive changes saw Michael Liebowitz appointed as CEO and Chairman following Howard M. Lorber’s retirement, potentially bringing fresh strategic direction given his extensive experience in financial services and insurance industries.
NYSE:DOUG Revenue & Expenses Breakdown as at Oct 2024
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Zhihu Inc. operates an online content community in the People’s Republic of China, with a market cap of approximately $334.15 million.
Operations: The company’s revenue segment includes Advertising, which generated CN¥4.06 billion.
Market Cap: $334.15M
Zhihu Inc., with a market cap of US$334.15 million, operates within the online content community sector in China. The company reported CN¥933.81 million in revenue for Q2 2024, although it remains unprofitable with a net loss of CN¥82.74 million. Despite its losses, Zhihu has made strides in reducing these over five years by 11.7% annually and maintains more cash than debt, indicating financial stability. A recent shareholders meeting considered buyback offers for Class A shares at HK$9.11 each (US$3.50 per ADS), reflecting strategic moves to enhance shareholder value amidst ongoing challenges in profitability and management experience concerns.
NYSE:ZH Debt to Equity History and Analysis as at Oct 2024
Embark on your investment journey to our 760 US Penny Stocks selection here.
Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio’s performance.
Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:QNCX NYSE:DOUG and NYSE:ZH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
